Erudio Healtherudio.com
Clinical trial · no report yet · Phase 1/Phase 2
TRESR trial: what clinicians have said so far
Study of RP-3500, Camonsertib, in Advanced Solid Tumors
- NCT04497116 ↗
- Completed
- Repare Therapeutics
- Focused size, estimated: 1–150 verified statements once built
We haven't built an HCP commentary report on TRESR yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on TRESR so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 3 posts on X, typically up to 13 once built |
The trial
ClinicalTrials.gov- Official title
- Phase 1/2a Study of the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Clinical Activity of RP-3500 Alone or in Combination With Talazoparib or Gemcitabine in Advanced Solid Tumors With ATR Inhibitor Sensitizing Mutations (TRESR Study)
- Phase
- Phase 1/Phase 2
- Status
- Completed
- Conditions
- Advanced Solid Tumor
- Interventions
- RP-3500 (camonsertib); Talazoparib; Gemcitabine Injection
- Arms
- RP-3500 (camonsertib) alone · Experimental
- Expansion cohorts with RP-3500 (camonsertib) · Experimental
- RP-3500 (camonsertib) with Talazoparib or Gemcitabine · Experimental
- Enrollment
- 276
- Primary outcomes
- Frequency of Treatment-Related Adverse Event of CTCAE Grade 3 and Above
- Frequency of Dose Limiting Toxicity (DLT)
- Sponsor
- Repare Therapeutics
- Start
- Jul 22, 2020
- Primary completion
- Jun 13, 2025
- Results posted
- Yes
- Registry record
- NCT04497116 · updated Oct 21, 2025
Publications
linked from the registry- Fontana E, Rosen E, Lee EK, Hojgaard M, Mettu NB, Lheureux S, Carneiro BA, Cote GM, Carter L, Plummer R, Mahalingam D, Fretland AJ, Schonhoft JD, Silverman IM, Wainszelbaum M, Xu Y, Ulanet D, Koehler M, Yap TA. Ataxia telangiectasia and Rad3-related (ATR) inhibitor camonsertib dose optimization in patients with biomarker-selected advanced solid tumors (TRESR study). J Natl Cancer Inst. 2024 Sep 1;116(9):1439-1449. doi: 10.1093/jnci/djae098. PubMed 38710487
- Yap TA, Fontana E, Lee EK, Spigel DR, Hojgaard M, Lheureux S, Mettu NB, Carneiro BA, Carter L, Plummer R, Cote GM, Meric-Bernstam F, O'Connell J, Schonhoft JD, Wainszelbaum M, Fretland AJ, Manley P, Xu Y, Ulanet D, Rimkunas V, Zinda M, Koehler M, Silverman IM, Reis-Filho JS, Rosen E. Camonsertib in DNA damage response-deficient advanced solid tumors: phase 1 trial results. Nat Med. 2023 Jun;29(6):1400-1411. doi: 10.1038/s41591-023-02399-0. Epub 2023 Jun 5. PubMed 37277454